The impact of PEAR 1 polymorphism on clinical outcomes in Chinese patients receiving dual antiplatelet therapy after percutaneous coronary intervention: Supplementary figure
Background: Patients might still experience major adverse cardiovascular events even with dual
antiplatelet therapy after percutaneous coronary intervention. Our study aimed to explore the impact
of gene polymorphism on clinical outcomes in one-year follow-up. Methods: A total of 171 patients
treated with dual antiplatelet therapy after percutaneous coronary intervention from April to December
2020 in the first hospital of Jilin University enrolled in this study. Results: PEAR1 genetic polymorphisms
was associated with the arachidonic acid (AA) and adenosine diphosphate (ADP) platelet aggregation.
Hyperglycemia was associated with the rate of major adverse cardiovascular events. PEAR1 GA+AA
genetic genetic polymorphisms is associated with hyperglycemia. Conclusion: PEAR1 GG is a risk factor
for AA and ADP platelet aggregation. Hyperglycemia can effect the one-year outcome. PEAR1 GA+AA
genetic polymorphisms are associated with hyperglycemia.